Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:FOLD News 19 December 2025 - 22 December 2025

BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025)

BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025)

BioMarin shares fell 3.5% to $58.98 on Dec. 22 after analysts weighed in on its $4.8 billion Amicus Therapeutics acquisition and the company confirmed it ended development of BMN 349. Truist Securities raised its price target to $100, citing strategic fit, while other analysts questioned the deal’s impact on growth and balance sheet risk.
22 December 2025
··
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

BioMarin agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at $4.8 billion. FOLD traded near $14.22 on December 22, reflecting market expectations for deal completion and timing. The transaction is expected to close in Q2 2026, pending regulatory and shareholder approvals. Either party may terminate if not closed by June 19, 2026, with a $175 million breakup fee.
22 December 2025
··
Amicus Therapeutics (FOLD) Stock News Today: BioMarin’s $14.50 Buyout, Fresh Analyst Forecasts, and Key Dates to Watch (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock News Today: BioMarin’s $14.50 Buyout, Fresh Analyst Forecasts, and Key Dates to Watch (Dec. 22, 2025)

Amicus Therapeutics shares traded near $14.18 on Dec. 22, 2025, following BioMarin Pharmaceutical’s agreement to acquire the company for $14.50 per share in cash. Both boards have approved the $4.8 billion deal, with closing expected in Q2 2026 pending regulatory and shareholder approval. The narrow price spread reflects typical merger-arbitrage dynamics. Citigroup reaffirmed a Neutral rating and set a $14.50 target.
22 December 2025
···
Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at about $4.8 billion. Amicus shares traded at $14.18 on Dec. 22, reflecting market focus on deal completion. TD Cowen downgraded Amicus to Hold, setting a $14.50 target. The deal is expected to close in Q2 2026, pending approvals.
22 December 2025
··
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

BioMarin Pharmaceutical agreed Friday to acquire Amicus Therapeutics for $14.50 per share in cash, valuing the company at $4.8 billion. FOLD shares closed near $14.18 after jumping 30% on the news. The deal is expected to close in Q2 2026, pending shareholder and regulatory approvals. Amicus disclosed a $175 million breakup fee and a June 19, 2026 outside date.
22 December 2025
····
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is ending 2025 with a bang. Shares surged on Friday, December 19, closing at $61.15—up 17.71% on the day—after the company announced a $4.8 billion all-cash acquisition of rare-disease peer Amicus Therapeutics. Trading volume spiked to roughly 18.5 million shares, far above BioMarin’s recent daily activity, underscoring how dramatically the market repriced the story in a single session. Investing.com+2Reuters+2 As of Sunday, December 21, 2025, the weekend narrative around BioMarin stock is dominated by that deal—and what it signals: a sharper pivot toward durable rare-disease commercial franchises, an attempt to reduce dependence on BioMarin’s fast-growing
21 December 2025
···
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) has effectively shifted from a “biotech story stock” to a deal-driven stock. The reason is simple and decisive: BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire Amicus in an all-cash transaction priced at $14.50 per share, putting a hard cap on the near-term upside—unless a competing bid emerges. SEC+1 With U.S. markets closed for the weekend, the most recent close available is $14.18 (Dec. 19, 2025)—a roughly 30% one-day jump that pushed shares close to the deal price and turned the remaining gap into a classic merger-arbitrage spread. StockAnalysis Below
21 December 2025
···
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology stocks head into the Christmas-shortened trading week with fresh momentum—and plenty for investors to digest—after a dense run of catalysts between December 19 and December 21, 2025. In the span of 48 hours, the sector saw a major rare-disease acquisition, a closely watched FDA approval in cardiology, IPO paperwork from both biotech and medtech, and a sweeping wave of U.S. drug-pricing headlines that could reshape sentiment into 2026. Investopedia+4Reuters+4Reuters+4 The setup matters because next week’s market structure will be unusual: U.S. stock markets are scheduled to close early on Wednesday, December 24 (1:00 p.m. ET) and remain closed on
21 December 2025
·····
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (Nasdaq: FOLD) has effectively become a “deal stock” — the market is now trading the shares primarily on the odds and timing of a takeover rather than on classic biotech catalysts. The reason is simple: on December 19, 2025, BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus for $14.50 per share in cash, valuing Amicus at about $4.8 billion. SEC+1 With U.S. markets closed this weekend, the last meaningful read is Friday’s action: Market data services show Amicus closing around $14.20 on Dec. 19, with trading also widely reported near
21 December 2025
··
Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has become one of the most closely watched rare-disease stocks heading into the final stretch of 2025 after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at about $4.8 billion. The offer price—$14.50 per share in cash—instantly reset the “center of gravity” for FOLD shares and shifted investor focus from traditional biotech catalysts (quarterly launches, pipeline readouts, reimbursement updates) to merger timing, regulatory approvals, and closing risk. SEC+1 As of the latest available pricing around Dec. 20, 2025 (UTC), Amicus shares were trading around $14.18, after a sharp, deal-driven
21 December 2025
··
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50 per share in cash, a premium of about 33% to Amicus’ prior close. Reuters+2BioMarin Corporate+2 On December 19, FOLD shares surged and closed at $14.18, just below the cash consideration—leaving a small spread that now reflects time to close, regulatory clearance, and deal risk rather than day-to-day biotech sentiment. Finviz+1 Below is a comprehensive roundup of the latest news, forecasts,
20 December 2025
···
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50 per share sparked a sharp re-pricing of Amicus shares, which have been hovering just below the bid as investors weigh deal timing, closing risk, and what the buyout means for Amicus’ two commercial rare-disease franchises—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease). SEC+1 Below is a detailed breakdown of the latest news (as of 20.12.2025), plus the most relevant
20 December 2025
·····
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is having the kind of week biotech traders both crave and fear: a sudden, definitive catalyst that snaps the stock to a new reality overnight. On Friday, December 19, shares jumped about 30% and hovered around $14.18, after BioMarin Pharmaceutical announced a $14.50-per-share all-cash acquisition valuing Amicus at roughly $4.8 billion. Reuters+1 Because it’s a cash buyout, the story for Amicus stock is now less about “quarterly beats” and more about a single question: Will the deal close on time and on the stated terms? And that question—plus a few spicy subplots like patent litigation
20 December 2025
··
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical is set to deepen its push into rare metabolic diseases after announcing a definitive agreement to acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion. The deal would add two marketed therapies—Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease—while also bringing in a Phase 3 kidney-disease program that could widen BioMarin’s late‑stage pipeline. BioMarin Corporate+1 The acquisition is the latest example of a larger biotech company using M&A to secure near‑term revenue and strengthen long‑term growth, particularly in rare disease categories where commercialization requires specialized manufacturing, reimbursement know‑how, and tight engagement with
19 December 2025
····

Stock Market Today

Go toTop